Table 1.

Sample characteristics and demographics (N=460)

Sample characteristics	Study entry M (SD)/N (%)	6-Week N (%)	12-Week N (%)	18-Week N (%)	24-Week N (%)
Age	56.35 (12.61)
Ethnicity
Asian	24 (5.20)
White/European American	311 (67.60)
Latina	89 (19.30)
Black/African American	10 (2.20)
Multiracial	8 (1.7)
Other	18 (4.0)
Income
Less than $50,000	124 (28.50)
$50,000–$74,999	97 (22.30)
$75,000–$100,000	57 (13.10)
More than $100,000	157 (36.10)
Employment
Employed	236 (52.10)
Not employed	83 (18.30)
Retired	134 (29.60)
Education
High school or less	114 (23.10)
2-year college	91 (20.00)
4-year college	164 (36.10)
Advanced Degree	85 (18.80)
Relationship status
Significant other	317 (69.70)
No significant other	138 (30.30)
Study site
Arizona	163 (35.4)
Los Angeles	297 (64.6)
Physical comorbidities	1.85 (1.88)
Months since diagnosis	2.13 (0.81)	3.79 (1.01)	5.21 (1.14)	6.54 (1.03)	7.99 (1.01)
Stage
1	197 (43.80)
2	176 (39.10)
3	52 (11.60)
4	25 (5.60)
Chemotherapy in the past 6 weeks	183 (41.7)	167 (42.3)	110 (28.4)	53 (13.8)	27 (7.0)
Surgery in the past 6 weeks	270 (59.6)	57 (14.4)	43 (11.1)	59 (15.4)	48 (12.5)
Taking estrogen antagonist	30 (6.6)	45 (11.5)	53 (13.8)	67 (17.5)	85 (22.1)
Taking aromatase inhibitor	37 (8.0)	64 (16.3)	71 (18.4)	75 (19.6)	79 (20.6)
Radiation therapy in the past 6 weeks	31 (7.0)	35 (8.9)	19 (4.5)	44 (11.5)	39 (10.1)
Herceptin use in the past 6 weeks	72 (15.9)	75 (19.1)	80 (20.7)	82 (21.4)	79 (20.5)
Completed last treatment in the last 6 weeks	112 (24.5)	54 (11.8)	48 (10.5)	75 (16.4)	168 (36.8)